AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact

Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.

Revenue report
AbbVie continues to work to maintain US access to Humira after biosimilars reach market • Source: Shutterstock

How AbbVie Inc. will perform financially once top-seller Humira (adalimumab) faces biosimilar competition has been an underlying question during every quarterly earnings call the pharma has convened since its split from Abbott Laboratories Ltd in 2013. But now, as that day draws closer, analysts and investors are seeking specific answers.

During AbbVie’s third quarter 2022 earnings conference call on 28 October, CEO Rick Gonzalez said things are on track for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.